Coronavirus Diesease-2019 (COVID-19) infection is suspected to affect the sexual behavior and function. The vascular damage related to COVID-19 can affect the impairment of bed blood vessel of penile and finally make the erectile dysfunction (ED). This problem is one of the most common sexual problem in man, with the prevalantion between 13 until 28% at the 40-80 years old, and the incidence increases with higher age. At this time, no data about the effect of COVID-19 to sexual behavior. There was one case of COVID-19 with erectile dysfunction who was treated at Kemayoran Athletes Village COVID-19 hospital. Erectile dysfunction is influenced by several factors; including psychogenic, neurogenic, and infectious. The diagnosis of erectile dysfunction is determined based on the results of history taking and physical examination, using the standard questionnaire (IIEF-5/International index of erectile function-5). A further review is needed to exclude a particular cause, the management can be determined based on the etiology.

Uterine leiomyosarcoma is a rare malignancy and is difficult to diagnose preoperatively. In this case series, we retrospectively reassessed ultrasound findings of 18 leiomyosarcoma cases and proposed the diagnostic workup. We are select seven ultrasound features and found irregular tumor border in 100%, loss of normal myometrium >25% in 61.11% (12 cases), loss of typical benign leiomyoma feature >50% in 77.78%, necrosis in 85.7% (16 cases), and cystic degeneration in 83.3% (15 cases). Circumferential vascularity was absent or minimal in 66.7% of cases, whereas intralesional vascularity with minimal or moderate intralesional vascularity was seen in 12 (66.7%) cases. Diagnosis of suspected uterine leiomyosarcoma requires five out of these seven features present, four gray‐scale and one color Doppler ultrasound.

Results: Twenty patients were accrued. 55% was male. All patients had clinical T3 N positive disease except one had T4 disease. Pathological response was evaluable in 19 patients. Dworak TRG 1-2 and 3-4 were detected in 36.8% and 63.2% respectively. After median follow-up of 5.93 years, five patients (25%) developed recurrent distant metastatic disease and finally expired. No recurrent disease occurred after 2.39 years. The 5-year DFS and OS were 75% and 80% respectively. Although no statistically significant difference was found, patients with Dworak TRG 1-2 had lower 5-year DFS and OS than those with TRG 3-4 (TRG 1-2, DFS 66.7% vs. TRG 3-4, DFS 100%, p¼.058 and TRG 1-2, OS 66.7% vs. TRG 3-4, OS 100%, p¼.059 respectively). At present, all patients with Dworak TRG 3-4 are alive and have never had recurrent disease. Conclusions: Most locally advanced rectal cancer patients receiving preoperative concurrent CapeOx/RT achieved best Dworak TRG. Long-term outcomes of these patients, especially with good response, were excellent. Larger studies may be needed to determine the association of Dworak TRG and survival. Legal entity responsible for the study: Ramathibodi Comprehensive Cancer Center.

Objective: To evaluate the impact of pathogenic BRCA1/2 tumor mutation on advanced stage-high grade serous epithelial ovarian cancer (HGSOC) survival outcome. Methods: A total of 68 from 144 patients were diagnosed with FIGO 2014 stage IIB-IV HGSOC between January 1st 2015, until March 31st 2021, at Dr. Cipto Mangunkusumo National Central Referral Hospital, Persahabatan Central Referral Hospital, and MRCCC Central Referral Hospital Siloam Jakarta, underwent NGS tumor BRCA1/2 gene testing and were included in this cohort historical study. We compared patient’s overall survival outcomes to pathogenic BRCA1/2 tumor mutational status. The patient’s clinicopathological characteristic factors that might affect patient’s survival outcomes were also investigated. Results: In the group with pathogenic BRCA1/2 tumor mutation, the likelihood of dying was 86% ​​lower (adjusted RR 0.149; 95%CI 0.046-0.475; p-value=0.001), and the median survival was better (median 46 months; 95%CI 34.009-57.991; p value=0.001) than the group without pathogenic BRCA1/2 tumor mutations (median 23 months; 95%CI 15.657-30.343; p value=0.001). The multivariate analyses identified pathogenic BRCA1/2 tumor mutation as an independent favorable prognostic factor for survival outcome (adjusted RR 0.149; 95%CI 0.046-0.475; p-value=0.001).Conclusions: In advanced stage-HGSOC patients, the pathogenic BRCA1/2 tumor mutations group have a better prognosis with longer survival outcomes than those without pathogenic BRCA1/2 tumor mutations.